• New Non-Opioid Pain Medication: Journavx

  • Feb 11 2025
  • Duración: 10 m
  • Podcast

New Non-Opioid Pain Medication: Journavx

  • Resumen

  • Fibromyalgia is an amplifier: any type of pain we experience, fibromyalgia cranks it up a notch. At the same time, we know that it’s crucial to treat pain early. Once we experience an injury or some trigger of acute pain, it’s important to address it as soon as possible to reduce the risk of it becoming a chronic issue.

    For many of us with fibromyalgia, pain medication is essential not just for those injuries leading to acute pain but also on our highest pain days or when we’re having breakthrough pain during a flare. In those cases, we need to have options for pain management, and it’s encouraging to see these options being expanded.

    Today, Tami discusses the recent FDA approval of the non-opioid pain medication Journavx. She explores how it works, potential benefits for people with fibromyalgia, why it’s crucial to treat pain early, potential side effects and medication interactions related to Journavx, Tami’s optimism about ongoing research and the potential benefits for fibromyalgia patients, and more.

    Note: This episode is not meant to be medical advice. Every person and every situation is unique. The information you learn in this episode should be shared and discussed with your own healthcare providers.

    To learn more about the resources mentioned in this episode, visit the show notes.

    For daily doses of hope, inspiration, and practical advice, join Tami on Facebook or Instagram.

    Need a good book to read? Download Tami's books for free.

    Ready to take back control of your life and health? Schedule a complimentary consultation with a Certified Fibromyalgia Coach®.

    Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre New Non-Opioid Pain Medication: Journavx

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.